tiprankstipranks
Trending News
More News >
JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
Japanese Market

JCR Pharmaceuticals Co., Ltd. (4552) Price & Analysis

Compare
1 Followers

4552 Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

1.48%97.28%
Insiders
1.48%
Mutual Funds
― Other Institutional Investors
97.28% Public Companies and
Individual Investors

4552 FAQ

What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?
JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥386.00 and its highest was ¥765.00 in the past 12 months.
    What is JCR Pharmaceuticals Co., Ltd.’s market cap?
    JCR Pharmaceuticals Co., Ltd.’s market cap is ¥70.54B.
      When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?
      JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is Jul 23, 2025 which is in 43 days.
        How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?
        JCR Pharmaceuticals Co., Ltd. released its earnings results on May 13, 2025. The company reported -¥33.8 earnings per share for the quarter, beating the consensus estimate of -¥53.704 by ¥19.904.
          Is JCR Pharmaceuticals Co., Ltd. overvalued?
          According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does JCR Pharmaceuticals Co., Ltd. pay dividends?
            JCR Pharmaceuticals Co., Ltd. pays a Annually dividend of ¥20 which represents an annual dividend yield of 3.51%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here
              What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?
              JCR Pharmaceuticals Co., Ltd.’s EPS estimate is 16.96.
                How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?
                JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.
                  What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?
                  JCR Pharmaceuticals Co., Ltd. reported an EPS of -¥33.8 in its last earnings report, beating expectations of -¥53.704. Following the earnings report the stock price went up 2.972%.
                    Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?
                    Currently, no hedge funds are holding shares in JP:4552

                    Company Description

                    JCR Pharmaceuticals Co., Ltd.

                    JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

                    4552 Stock 12 Month Forecast

                    Average Price Target

                    ¥600.00
                    ▲(5.26%Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"496":"¥496","626":"¥626","756":"¥756","886":"¥886","1016":"¥1,016"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥600.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥600.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥600.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[496,626,756,886,1016],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Oct<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,497,504.9230769230769,512.8461538461538,520.7692307692307,528.6923076923077,536.6153846153846,544.5384615384615,552.4615384615385,560.3846153846154,568.3076923076923,576.2307692307693,584.1538461538462,592.0769230769231,{"y":600,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,497,504.9230769230769,512.8461538461538,520.7692307692307,528.6923076923077,536.6153846153846,544.5384615384615,552.4615384615385,560.3846153846154,568.3076923076923,576.2307692307693,584.1538461538462,592.0769230769231,{"y":600,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,497,504.9230769230769,512.8461538461538,520.7692307692307,528.6923076923077,536.6153846153846,544.5384615384615,552.4615384615385,560.3846153846154,568.3076923076923,576.2307692307693,584.1538461538462,592.0769230769231,{"y":600,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1015.77,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":856.04,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":812.75,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":786.63,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":555.38,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":594.08,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":550.54,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":592.15,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":592.15,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":648.94,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":595.92,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":542.91,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":497,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Nihon Chouzai Co
                    Sosei Group
                    Mochida Pharmaceutical Co., Ltd.
                    KYORIN Pharmaceutical Co.,Ltd.
                    ASKA Pharmaceutical Holdings Co., Ltd.
                    Popular Stocks
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis